Background--Impact of liver disease on development of atrial fibrillation (AF) is unclear. The purpose of the study was to evaluate prevalence of AF in the setting of liver disease and whether increasing severity of liver disease, using Model for End-Stage Liver Disease (MELD), is independently associated with increased risk of AF.
L
iver disease can affect circulating inflammatory peptides and lead to autonomic dysfunction, creating a proarrhythmic substrate. [1] [2] [3] [4] An elevated risk of atrial fibrillation (AF) among patients with liver disease and structurally normal hearts seems plausible given that inflammation and autonomic dysfunction have been shown to contribute to pathogenesis of AF. 5 However, studies on incidence and prevalence of AF in patients with liver disease are few and have shown mixed results. 6, 7 In addition, results of these studies have been confounded by the lack of assessment of liver disease severity in the specific population studied. In this study, we hypothesized that the risk of new-onset AF is driven by severity of liver disease. We therefore hypothesized that increasing Model for End-Stage Liver Disease (MELD) values is associated with new-onset AF, after adjusting for other comorbidities and risk factors.
Methods
As per the Journal of American Heart Association (JAHA) implementation of transparency and openness policy, the data, analytical methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure upon request.
Study Population
Retrospective data analysis of consecutive patients who were diagnosed with liver disease between January 2006 and December 2015 and were evaluated for potential liver transplantation (LT) was performed. The electronic health records database was made available by the University of California, Los
Angeles Clinical and Translational Science Institute, supported by the NIH/National Center for Advancing Translational Science University of California Los Angeles Clinical and Translational Science Institute Grant No. UL1TR000124. This study was reviewed and approved by the University of California Institutional Review Board (Los Angeles, CA). Requirement for patient informed consent was waived given the retrospective nature of the study. Baseline patient characteristics were noted at the time of first available MELD score.
MELD Score
Severity of liver disease was assessed by MELD score and calculated using the formula:
MELD Score ¼ 9:57 Â Log e ðcreatinine mg/dLÞ þ 3:78 Â Log e ðbilirubin mg/dLÞ þ 11:20 Â Log e ðINRÞ þ 6:43:
MELDvaluesforeachpatientwerecalculatedandusedforsurvival analysis.MELDscoresconfoundedbyuseofwarfarin andargatroban were treated as unknown values and excluded from analysis.
Baseline Characteristics and Assessment of AF
Baseline characteristics were collected from patient medical records, including physician notes, laboratory results, medications, billing codes, ECGs, ambulatory monitors, and echocardiograms. AF diagnosis was obtained from physician notes and billing codes and verified by detailed review of medical records, which included review of all available ECGs and ambulatory monitors. AF prevalence was calculated using the last available time point preceding LT and after the first presentation for clinical evaluation for liver disease or LT. Severe valvular heart disease was assessed from echocardiographic reports and defined as presence of any severe valvular regurgitation or stenosis. Echocardiographic reports were also used to evaluate for moderate or severe left atrial (LA) enlargement. To assess whether severity of liver disease was associated with new-onset AF, occurrence of new-onset AF after first available MELD score was assessed. Patients were followed up until occurrence of LT, death, or loss to follow-up. Patients were then binned into quartiles of MELD categories, which included those with MELD score of 1 to 10 as the lowest quartile, followed by 10 to 20, 20 to 30, and >30. Percentages of patients with missing variables are shown in Table S1 .
Statistical Analysis
Continuous variables were assessed as means with SDs or medians with 25% to 75% percentiles, and categorical variables as percentages. Patient characteristics by occurrence of AF were assessed using a 2-tailed Student t test. Univariable analyses of patient characteristics were performed during the time frame of MELD score availability. Clinically relevant variables, such age and sex, as well as statistically significant variables (P<0.05) on univariable analysis, were included in the multivariable analysis. Multivariable time-dependent Cox regression analysis was performed to analyze the effect of MELD score on incidence of new-onset AF, adjusted for age, sex, reduced left ventricular (LV) ejection fraction (LVEF) <50%, LA enlargement, LV hypertrophy, severe valvular heart disease, portal hypertension, hypertension, diabetes mellitus, hemodynamic instability, and sleep apnea. Missing data were imputed using an Expectation-Maximization algorithm developed by Honaker et al for missing data in time series and 15 multiply imputed data sets generated. 8 All estimates were combined using Rubin's rules and P values combined using methods from Meng and Rubin and Marshall et al. [9] [10] [11] In addition, the multivariable time-dependent Cox regression analysis was also performed on available (nonimputed data) to further confirm the results. For survival analysis, only patients with at least 2 MELD scores from distinct dates were considered for analysis. All analyses were performed using the R statistical package (Version 3. Baseline characteristics are shown in Table. Mean MELD score in the overall population was 17.5AE8.5, and 28% of patients underwent LT at the end of follow-up. Mean LVEF was 61AE8%, sleep apnea was present in 0.5%, severe valvular heart disease in 0.3%, and moderate or severe LA enlargement was 0.3%. LV hypertrophy was present 0.5%, and LV diastolic dysfunction was present in 6.4% of the population. Beta-blocker use at baseline in the population was 5.7%, and during the follow-up period, was 11.9 new prescriptions per 100 patient years. Baseline CHA 2 DS 2 -VASc was 0.83 at baseline and baseline HAS-BLED score was 2.0. Including pre-existing AF at the time of evaluation, overall prevalence of AF among this population was 11.2% (confidence interval [CI], 9.8-12.7). AF prevalence by final MELD score (Figure 1 ) was 3.7% in the lowest MELD quartile and 20.2% in highest quartile. Freedom from AF ( Figure 2 ) decreased over time with 8.5% of patients experiencing new-onset AF over the median follow-up period. Incidence of new-onset AF by MELD categories (1-10, 11-20, and 21-30) over a 12-month period is shown in Figure 3 . There was a trend of increasing incidence of AF as MELD severity increased (P=0.056). Of note, patients in the highest MELD group (>30) had a very short median follow-up time (<1 month) attributed to either death or LT. 
Predictors of New-Onset AF
On univariable analysis (Table S2) , variables commonly associated with AF, including age, severe valvular heart disease, hemodynamic instability, LVEF, LA enlargement, and sleep apnea, were significantly associated with new-onset AF. Therefore, these variables, in addition to categories of MELD score, were included in the final multivariable analysis, which included: age, diabetes mellitus, hemodynamic instability, hypertension, LA enlargement, LV hypertrophy, MELD score groups (1-10, 11-20, 21-30, and >30), portal hypertension, LVEF, sleep apnea, and valvular heart disease. Patient characteristics by occurrence of new-onset AF are shown in Table S3 . Using multivariable time-dependent Cox proportional hazard regression analysis (Figure 4 ), increasing severity of MELD was independently associated with new-onset AF. Specifically, as compared with patients in the lowest quartile (MELD 1-10 Figure 4 . Similar results were obtained with the Cox proportional hazard model using available (nonimputed) data (Table S4) .
With regard to stroke, rate of stroke was 1.6 events per 100 years of follow-up in patients with AF (ischemic stroke rate of 1.3% and hemorrhagic stroke rate of 0.6%). CHA 2 DS 2 -VASc score in these patients was 1.1AE1.0, likely explaining the low incidence of stroke in this patient population with otherwise low comorbidities. Risk of stroke (both ischemic and hemorrhagic) did significantly increase with increasing MELD score (P<0.001; Tables S5 and S6).
Discussion Major Findings
In this large, retrospective study, incidence and prevalence of AF in liver disease was high and severity of liver disease, as measured by MELD, was found to be a novel risk factor for new-onset AF, after adjusting for other traditional risk factors.
End-Stage Liver Disease and AF
Although many variables play a role in the pathogenesis of AF, liver disease has not been traditionally viewed as 1 of these risk factors. The few studies that have evaluated prevalence and risk of developing AF in patients with liver disease have shown mixed results. Mwalitsa et al evaluated 335 patients with cirrhosis and found that, over 24 months of follow-up, there was no association between cirrhosis or MELD score and new-onset AF. It is possible that the small sample size of this study and the method used for verifying AF could have underestimated the incidence of AF in this population. 7 In another study of 1302 cirrhotic patients, incidence of AF was found to be very low at 0.15%, and this study suggested that liver disease may be protective against AF. However, in this study, disease severity was not assessed and intermittent ECGs were used for verification of AF diagnosis, leading to underdiagnosis of asymptomatic episodes. 13 On the other hand, Lee et al. focused on new-onset AF and found a 46% relatively higher risk of AF in cirrhotic patients compared with noncirrhotic patients. 6 Given the small number and controversial results of these previous studies, we hypothesized that severity of liver disease, as assessed by MELD score, would be independently associated with new-onset AF. We found that in our population of 1727 patients, prevalence of AF was high (11.2%) and increasing liver disease severity was associated with an increasing HR for new-onset AF, even after adjusting for other AF risk factors. Importantly, prevalence of AF in our study was higher than previously reported studies. This may be attributed to the fact that all patients in this study were followed by a cardiologist as part of their disease workup, which may have increased the detection of AF. In this study, we focused on analyzing the effect of liver disease on developing new-onset AF preceding transplantation. Perioperative AF, which can be associated with inflammation, complications at the time of surgery, and blood loss, has been previously shown to be associated with worse clinical outcomes acutely. Predictors of perioperative AF included MELD score and previous history of AF. 14 
Clinical Implications
Patients with liver disease have been traditionally viewed as having low cardiac comorbidities, with a focus placed on treatment of associated renal dysfunction and coagulopathy. A previous study had even suggested that liver disease may play a protective role against the development of AF. 13 Our study suggests that patients with cirrhosis are at increased risk of AF, with increasing risk of developing AF as their MELD score rises. Severity of liver disease was independently associated with increased risk of AF after adjusting for other traditional cardiac and noncardiac risk factors, such as sleep apnea. We noted an AF prevalence of 20.2% in patients with the highest MELD category with a new AF incidence of 8.5% at 12 months of follow-up in the overall population. Mean age of our population was only 54.4AE12 years. Based on a study by Wilke et al looking at 8.3 million people in Germany, prevalence of AF has been reported to be between 1% and 2% in men (ages 50-55 and 55-59 years, respectively) and 0.4% to 0.8% in women (ages 50-55 and 55-59 years, respectively) in the general population. 15 Incidence of AF in the same study was 0.3% and 0.5% in men (ages 50-55 and 55-59 years, respectively) and 0.12% to 0.26% in women (ages 50-55 and 55-59 years, respectively). 15 Prevalence and incidence of AF were much higher in our patient population with liver disease, despite the fact that many of the previously reported historical controls had presence of cardiac risk factors for AF, such as hypertension and heart failure. 15 High prevalence of AF, particularly as liver disease progresses, suggests that both cardiologists and hepatologists should be aware of the emerging risk of AF, inquire about arrhythmia symptoms, and consider periodic evaluations with ECGs and ambulatory monitors. Higher prevalence of AF as well as increasing incidence of AF with increasing severity of liver disease bring to the forefront the question of benefit versus risk of anticoagulation. The benefit of anticoagulation for ischemic stroke prevention in patients with liver disease and AF remains unknown. Few studies have evaluated the benefit of anticoagulation systematically or in a randomized fashion. Kuo et al evaluated liver disease patients with CHA 2 DS 2 -VASc score ≥2 in the setting of AF and showed a reduction in ischemic stroke events in patients treated with warfarin compared with those with and without antiplatelet therapy, notably without increased intracranial hemorrhage. 16 However, an increased risk of hemorrhagic stroke and intracranial hemorrhage has been reported in patients with cirrhosis as compared with those without, 17, 18 and in 1 study was reported to be higher than ischemic stroke risk. 19 A tailored strategy has been proposed and includes anticoagulation in the setting of lesssevere liver disease, while refraining from anticoagulation in more severe cirrhotic patients with AF. 20 The results of our study, demonstrating a high prevalence of AF and increasing incidence of AF in the setting of more-advanced liver disease, highlight the need for better designed studies in this specific population to define the benefit and risk of anticoagulation, particularly with the advent of novel oral anticoagulants. It is possible that patients at high risk of bleeding and stroke may also benefit from LA appendage closure devices, a question that could not be assessed in our study, given the low overall CHA 2 DS 2 -VASc score and low incidence of comorbidities in this population. It has been suggested that AF is associated with worsened outcomes in the perioperative period and immediate postoperative period in patients undergoing LT. 21, 22 Given the findings of this study, AF is likely a marker of illness severity rather than a major cause of poor outcomes.
Potential Mechanisms Behind Development of AF in Cirrhosis
Liver disease can directly or indirectly influence the pathogenesis of AF. The autonomic nervous system is known to play a significant role in development of AF. 5 Abnormal autonomic neurotransmission, with increased parasympathetic and sympathetic activation, is associated with AF. 23 Vagal afferent and efferent fibers also innervate the portal vein, hepatic arteries, and biliary ducts in addition to liver parenchyma. 24 Specifically, autonomic dysfunction has been observed in the setting of portal hypertension [1] [2] [3] and nonalcoholic fatty liver disease, 25 and denervation of liver parenchyma has been observed in cirrhosis. 26 Cardiac metaiodobenzylguanidine studies have shown an increased washout rate consistent with abnormal myocardial norepinephrine reuptake in patients with cirrhosis. In addition, patients with cirrhosis have been shown to have significantly decreased heart rate variability and baroreflex sensitivity, 27 with increased prevalence of abnormal heart rate variability with increasing severity of liver disease. 28 Finally, improvements in autonomic indices are observed post-LT. 29 Cirrhosis can also lead to increased levels of neuropeptides that have been shown to play a role in development of AF. Vasoactive intestinal peptide is increased in the setting of cirrhosis, possibly attributed to decreased turnover by the liver. 30, 31 Vasoactive intestinal peptide has also been implicated in the onset of vagally mediated AF. 32, 33 Whereas low and moderate levels of vagal nerves stimulation have been shown to be protective in preventing AF, vasoactive intestinal peptide is coreleased with acetylcholine during high-level vagal nerve stimulation, shortening action potential duration, increasing atrial action potential duration spatial heterogeneity, and causing intra-atrial conduction block. 33, 34 Another potential mechanism behind the elevated risk of AF in the setting of cirrhosis is the elevated levels of galectin-3 observed in patients with liver disease. 35, 36 Galectin-3 is implicated in fibrosis of both the liver and heart, and associated with increased incidence of AF. 37, 38 Other potential mediators that share the common pathway of fibrosis and could play a role include transforming growth factor beta 39 and connective tissue growth factor. 40 Also, many inflammatory cytokines, such as interleukin-6, interleukin-8, and tumor necrosis factor-alpha, 41 and oxidative radicals, such as superoxides and peroxynitrite, 42 are elevated in the setting of significant liver disease and also play a role in development of AF. [43] [44] [45] Finally, many circulatory cytokines and neuropeptides that play a role in AF are upregulated by the autonomic dysfunction that occurs in liver disease. 46 
Limitations
This study is a single-center retrospective study and represents outcomes at a specialized center for evaluation of patients with liver disease. To best capture AF prevalence, patients with cirrhosis undergoing evaluation for LT were selected, because this group at our center undergoes extensive and rigorous cardiac evaluation regardless of cardiac history. Focusing efforts on this population, however, may create a bias toward patients who do not have a significant burden of comorbidities that would preclude consideration for transplantation. However, using a population with less comorbidity allows for a more accurate assessment of the impact of liver disease on development of AF, the primary goal of this study. Using International Classification of Diseases, Ninth Revision (ICD-9) billing code data to identify comorbidities associated with AF, such as sleep apnea, has limitations. However, in this study, many of the risk factors previously reported to be associated with AF continued to be statistically significant in our multivariable model. Of note, in this study, manual chart review was performed to ensure that all AF diagnoses had also been documented on physician notes, ECGs, and ambulatory monitors in addition to ICD-9 codes. Finally, although we performed a review of all available clinical data to verify the diagnosis of AF, it is possible that patients with asymptomatic AF were overlooked, and therefore, despite the higher prevalence of AF observed in this study, it may yet represent a conservative estimate as to the true prevalence of AF in this population. Finally, we noted a higher prevalence and incidence of AF in patients with liver disease as compared with previous studies that reported the prevalence and incidence of AF by age in the general population. However, we did not have access to data of similar age-/sex-matched controls without liver disease with similar CHA 2 DS 2 -VASc scores to show a lower incidence of AF in a similar population without liver disease.
Conclusions
Prevalence of AF in patients with liver disease is notable.
Incidence of AF increases with increasing severity of liver disease, which is independently associated with new-onset AF, even after adjusting for other common risk factors. This finding may provide additional mechanistic insight into the pathogenesis of AF, which shares the underlying link of autonomic dysfunction and inflammation, known to play a role in development of AF. Given the prevalence of AF in this population, cardiologists and hepatologists should consider screening for symptoms and signs of AF in patients with liver disease, particularly in patients with higher MELD values. The results also highlight the need for future well-designed studies to evaluate risks and benefits of anticoagulation in the setting of liver disease.
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